Company Overview and News
Ablynx NV (OTC:ABYLY) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,883,306 shares. Largest shareholders include Van Herk Investments B.v..
Lead candidate caplacizumab has peak sales potential of €800 million and results from phase 3 HERCULES study were selected as one of only six oral abstracts to be presented at ASH. (69-0)
With investors opting for turkey over deals, Thanksgiving week was slow for the IPO market. Senior housing SPAC Big Rock Partners Acquisition (BRPAU) was the only company to come public, raising $60 million. This week, quiet periods expired for antibody biotech Ablynx (NASDAQ:ABLX), BP Midstream LP (Pending:BPMP), National Vision Holdings (NASDAQ:EYE), ForeScout Technologies (NASDAQ:FSCT), Merchants Bancorp (NASDAQ:MBIN) and Nexa Resources (Pending:NEXA). (32-3)
After a flurry of deals over the past two months, the pre-Thanksgiving rush has come to a close. No IPOs are pricing in the week ahead. However, this is the last week for most companies to submit initial filings with enough time to price IPOs before year-end. Quiet periods will expire for six recent IPOs this week, with street research expected for antibody biotech Ablynx (NASDAQ:ABLX), BP Midstream LP (Pending:BPMP), National Vision Holdings (NASDAQ:EYE), ForeScout Technologies (NASDAQ:FSCT), Merchants Bancorp (NASDAQ:MBIN) and Nexa Resources (Pending:NEXA). (46-1)
There were eight initial public offerings (IPOs) on the calendar last week and six succeeded in gaining access to the public markets. The total amount raised over $2 billion and the average first-day pop was around 13.7%. (95-0)
In another active week for the IPO market, six companies in six different sectors raised over $2 billion. Boasting strong comp growth, National Vision (NASDAQ:EYE) was the top performer with a 28% gain as investors put a premium on the Amazon (NASDAQ:AMZN)-proof retailer. The week's other two growth stories, cybersecurity unicorn ForeScout Technologies (FSCT) and antibody biotech Ablynx (Pending:ABLX), were also well received. (115-0)
* Ablynx NV - prices us IPO totaling $200 million proceeds from sale of 11.43 million shares in form of American depositary shares at price of $17.50/ADS Source text for Eikon: Further company coverage:
There were six initial public offerings (IPOs) on the calendar last week and five succeeded in gaining access to the public markets. The total amount raised was $2.15 billion and the average first-day pop was around 14%. (104-0)
The steady flow of IPOs in the 4Q is set to continue with six companies in six different sectors scheduled to raise a combined $2.1 billion in the week ahead. The diverse collection includes unicorn ForeScout Technologies (Private:SCOUT), an enterprise security software provider that hopes to follow the success of the most recent unicorn to IPO, MongoDB (Pending:MDB), which priced last week and popped 34% on its first day. (49-0)
· The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025, according to a new report by Grand View Research, Inc.
RnRMarketResearch.com adds "Bone Metastasis - Pipeline Review, H1 2017" therapeutic market research report of 100 pages with latest updates, data and information to its online business intelligence library. (0-1)
Good morning, ladies and gentlemen. It’s a pleasure to be with you here this morning and great to see you in full of Analysts and Investor interest in the ongoing Vectura. Welcome to those who listening on the telephone or on the webcast.
Chippenham, UK - 23 November 2016: Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading device and formulation business for inhaled airways products, today announces its unaudited interim results for the six months ended 30 September 2016.
The following slide deck was published by Ablynx NV in conjunction with their 2016 Q2 earnings call.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton